Renewed interest in phage therapy has seen a spike in compassionate use globally. The century old technique of using phages, the natural predators of bacteria, to treat infections is an attractive therapeutic option particularly given increasing antibiotic resistance rates and the impact of antibiotic use on the surrounding commensal microbiota. Moving away from compassionate use and looking towards the future of phage therapy, there are a number of potential perinatal applications likely to benefit the mother and fetus through reduced antibiotic exposure at this critical time in development. To understand how phage therapy may be a suitable treatment option during pregnancy and early life, it is vital we understand interactions between phages and the unique placental barrier. This talk will highlight the limited research that exists in this field and discuss new data regarding phage transfer across placental membranes. Further, it will document the special considerations that need to be addressed in a pregnant population prior to widespread use of phage therapy.